Skip to main content

Are you looking for something?

Actome GmbH and QIAGEN announce commercial partnership

The young start-up, which emerged from the environment of Hahn-Schickard and the University of Freiburg, is now marketing its protein interaction coupling technology (PICO technology) together with the life science company Qiagen GmbH Hilden.

Proteins control and direct biological processes through their interactions, the so-called interactome, by which they determine our health and wellbeing. Tools to study the interactome enable the understanding of cellular processes and open up an enormous potential for research, diagnostics and therapies. Tackling these challenges, Actome's innovative technology is a breakthrough that has the potential to revolutionize research and biomedicine.

The unique performance of Actome’s products is based on the patented PICO -Technology that detects single protein molecules and protein interaction complexes by translating protein status into DNA-barcodes. These barcodes are then detected by the method of digital PCR and decoded by a proprietary software developed by Actome.

Read the full press release by Actome GmbH (January 7, 2022)

Antibody A for protein A and antibody B for protein B are marked with different DNA barcodes. After mixing and incubation with the sample, the solution is converted into an emulsion of ten to one hundred thousand homogeneous microdroplets. Amplification methods such as PCR or isothermal amplification make the barcodes contained in each droplet visible, individually. Source: Hahn-Schickard
Back


Contact

Katrin Grötzinger

+49 761 203 73242 Contact

Competences

  • PR at the branch in Freiburg
  • Marketing
  • Press + Media
  • Events